Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 221 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL MOST POPULAR What People With Cancer and Survivors Should Know About Vaping: An... September 26, 2023 Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... November 14, 2023 Qué saber al buscar información sobre el cáncer en línea: perspectiva... August 11, 2022 Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... March 6, 2024 Load more HOT NEWS Precision drug slows progression of advanced breast cancer A new approach to cancer immunotherapy ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ
